January 5, 2024 10:23 AM ESTUpdated 11:05 AM

Boehringer’s deal spree; Praxis’ licensing pact with Shanghai biotech; Vico Therapeutics raises $60M

Kyle LaHucik

Senior Reporter

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Plus, news about PolyPid, Clarametyx Biosciences, Debiopharm, Repare Therapeutics, Immunic, Voyager Therapeutics, Kymera Therapeutics and Catalyst Pharmaceuticals:

Boehringer Ingelheim inks its third deal this week …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer’s deal spree; Praxis’ licensing pact with Shanghai biotech; Vico Therapeutics raises $60M

Kyle LaHucik

Senior Reporter

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

Boehringer’s deal spree; Prax­is’ li­cens­ing pact with Shang­hai biotech; Vi­co Ther­a­peu­tics rais­es $60M

Senior Reporter

News Reporter

Deputy Editor

Sign up to read this article for free.

Boehringer’s deal spree; Praxis’ licensing pact with Shanghai biotech; Vico Therapeutics raises $60M